Ligand Pharmaceuticals (LGND) Other Non-Current Liabilities (2010 - 2026)

Ligand Pharmaceuticals has disclosed Other Non-Current Liabilities across 17 years of filings, most recently posting $17.1 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $17.1 million, up 20.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.1 million (up 20.12% YoY), and the FY2025 annual result was $16.6 million, down 44.87% from the prior year.
• Other Non-Current Liabilities came in at $17.1 million for Q1 2026 at Ligand Pharmaceuticals, up from $16.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $43.7 million in Q3 2023 to a low of $14.2 million in Q1 2025.
• The 5-year median for Other Non-Current Liabilities is $21.9 million (2022), against an average of $24.4 million.
• Across the five-year window, Other Non-Current Liabilities jumped 98.96% in 2023 and slumped 51.04% in 2025, its largest moves.
• Ligand Pharmaceuticals' Other Non-Current Liabilities stood at $27.8 million in 2022, then changed by 0.0% to $27.8 million in 2023, then increased by 8.66% to $30.2 million in 2024, then tumbled by 44.87% to $16.6 million in 2025, then grew by 2.92% to $17.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $17.1 million (Q1 2026), $16.6 million (Q4 2025), and $19.9 million (Q3 2025), per Business Quant data.